Milife pills 500mg 30pcs

Product description

dietary supplements. It is not a medicinal product

Characteristics

Biomass of the monoculture of the higher fungus Fusarium sambicium, strain VSB-917.

It contains low-molecular-weight oligopeptide compounds, alkaline oligopeptides, and 18 amino acids (including essential tryptophan, lysine, and methionine).

The content of aspartic and glutamic amino acids is close to their content in animal proteins; unsaturated fatty acids (50% – linolenic acid); carbohydrates are represented by glycans, organic acids (including malic, citric, succinic); B vitamins (folic acid), nicotinic acid and Ubichinons Q6, Q9, Q10.

Mineral composition – 22 vital micro-and macronutrients.

Pharmacological action

Pharmaceutical group:

adaptogenic agent.

Pharmaceutical action:  

Pharmacological action-metabolic, tonic, adaptogenic, regenerating, detoxifying, immunomodulating, antiviral, genoprotective, antimalarial, antiparasitic.

The spectrum of action of the obtained effects when using the drug is so wide that it allows us to classify it as a systemic drug that detects and restores violations of information (restoration of correct genetic replications), functional, metabolic, and energy connections in the body, activating recovery and reparative processes at different levels. Such capabilities of the drug are due to a powerful antioxidant effect (blockade of the final stages of oxidative stress). It has a non-specific and specific antiviral effect.

The variety of biologically active compounds that are close in chemical composition to the complex membrane structure of a human cell determines the multivalent effect of Milife® on metabolic-endocrine-immune processes, having a corrective effect on all types of metabolism and homeostasis in general.

It represents the biomass of a monoculture of the higher fungus Fusarium sambucinum, strain VSB-917. Contains low-molecular-weight oligopeptide compounds, alkaline oligopeptides,18 amino acids, including all essential amino acids, which account for up to 45% of the total amount of amino acids of the drug.

The carbohydrate composition of the drug includes biologically active polysaccharides (glycans: glucans and galactomannans, lentinan). In addition, the composition of Milife® includes oxamic, malic, citric, succinic and other organic acids. The lipid fraction of the drug contains phospholipids, sterols, glycerides, fatty acids and Ubichinons.

More than 50% of the essential fatty acids that make up Milife® are linoleic and linolenic acids, which are not synthesized in the human body and must come from food.

Milife® contains a full complex of B vitamins.

Milife® contains a balanced set of macro-and microelements in the easily digestible form of organic compounds and complexes.

From the first days of use, the positive activity of Milife® begins to manifest itself at the molecular and cellular level in those organs and systems that have the most profound and gross violations.

Milife®, acting on the mesodiencephalic structures of the brain, finds the ” Locus minoris “(“place of least resistance”) in the body and acts on it selectively and consistently.

Milife® has a general strengthening and adaptogenic effect, increases the body’s resistance to the effects of the endoecological environment, increases the body’s resistance to stress, preventing secondary post-stress consequences. Increases mental and physical performance, as well as accelerates recovery from exertion and diseases of various etiologies. This is made possible by the powerful antioxidant effect of the drug.

The drug Milife ® increases proliferative activity (division activity) in cells and controls the cell cycle, triggers an accelerated apoptosis system in defective cells, which leads to a slowdown in the accumulation of mutations.

Milife® frees cells from genetically redundant (extrachromosomal)DNA. DNA as a result of increased vesicular traffic (intra-and intercellular transport in membrane vesicles). The result is the suppression of defective sequences and an increase in the accuracy of replication of existing sequences in DNA, which allows the use of Milife® for the prevention of cancer and for suppressing the progression of malignant cells during cancer therapy.

Milife ® has a bioregulatory multidirectional effect that can enhance a weak, weaken a strong or leave the normal response of the immune system unchanged.

As a result of experimental studies and clinical trials, it was established that Milife® affects immunocompetent organs, contributes to the normalization of indicators of both cellular and humoral immunity. Causes the effect of a colony-stimulating factor in immunocompetent organs, increasing the renewal of lymphoid cells by 1.7-2.1 times. Restores the entire interleukin series (from IL-1 to IL-18). As an inducer of alpha -, beta – and gamma-interferon, a tumor necrosis factor (alpha/beta), the drug increases the number of natural killers (CD16), increases the number of B-lymphocytes, increases the immunoregulatory index (ratio of helpers and suppressors) by increasing cytotoxic T-lymphocytes (CD8) and T-helper cells (CD4).

Given the effect of Milife® on immune-competent organs and increased vesicular traffic, the neuroimmune system is able to recognize pathological changes in the cell and the cause of these changes, in particular the virus. The consequence of this is a specific and non-specific antiviral effect of the drug.

Milife® induces cellular and humoral immunity by increasing cytotoxic T-lymphocytes (CTL), which recognize the presented antigens by restoring the function of proteins of the main histocompatibility complex (MHC) and lyse infected cells. Milife® has a direct virucidal effect, i. e. it destroys the virus by acting directly on its structures, even if the virus is in a latent form.

Promotes virus elimination by eliminating virus-producing cells. Against the background of the drug’s action, B-lymphocytes form a wide range of soluble antibodies that neutralize the virus, and support the immune response by increasing the number of active B-lymphocytes of long-term memory and increasing the duration of persistent expression of the virus antigen. The drug even helps inactivate the virus until it has a chance to infect new host cells.

The resulting antibodies mobilize the inflammatory system, including the complement system, neutrophils, and monocytes. Thus, even when the antibodies do not directly neutralize the virus, there is a possibility that other effector functions of the antibodies will be enhanced by using the inflammatory system. The drug does not allow the virus to acquire the properties of resistance and evolve.

A wide spectrum of antiviral activity of the drug indicates the presence of pronounced immunological mechanisms of action, which is confirmed by studies conducted at the Gamaley Research Institute of Epidemiology and Microbiology and the Gamaley Research Institute of Virology and Epidemiology. Ivankovsky.

Milife ® has specific activity against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae both in the prophylactic regimen and when taking the drug 72 and 96 hours after infection.

The data obtained on the high specific activity of Milife® against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae are consistent with the data on the pronounced antiviral and immunostimulating activity of Milife®in experimental influenza infection, infections caused by encephalitis viruses and other viruses, and confirm its antiparasitic effect (yellow fever, malaria, toxoplasmosis and leishmaniasis).

Milife ® has a hepatoprotective effect, normalizes impaired detoxification and protein-forming liver function by activating many isoforms of cytochrome P%^%450.

Milife® does not contain doping components (Expert Opinion No. S068S of the Anti-Doping Center dated May 24,2008) and can be recommended for wide use in sports medicine.

Based on the conducted studies, it can be stated that Milife® with course application restores the physical and mental performance of athletes, has a modeling effect on the clinical, biochemical and immunological parameters of blood.

Pharmacokinetics:  

After oral use, the drug is rapidly absorbed. Maximum activity is reached in 90 minutes. Bioavailability is almost complete. The degree of binding to plasma proteins is up to 6%, the volume of distribution is 1.8-1.9 l / kg.

The drug quickly penetrates into tissues, organs and body fluids — heart muscle and heart valves, liver, spleen, adrenal glands, kidneys, gallbladder, pancreas, uterus, prostate, bones, abdominal and pleural cavities, saliva, sputum. The concentration of Milife® in tissues and organs is higher than the concentration in blood plasma.

The drug is mainly excreted in the urine (up to 70% within 72 hours) and partially with bile — up to 25%.

Indications

chronic fatigue syndrome and immune dysfunction;

complex therapy for the treatment of viral and toxic liver damage (including alcoholic origin);

immunodeficiency and immunosuppression;

complex therapy for the treatment of autoimmune diseases (autoimmune thyroiditis, diabetes mellitus);

as a therapeutic and prophylactic agent in influenza, latent herpetic (6 types of herpes virus), chlamydia, ureaplasmosis infections; infections of HIV and hepatitis C, and infections caused by pathogens such as yellow fever and malaria;

to conduct radiation and chemotherapy in cancer patients;

the preoperative period and postoperative rehabilitation;

neuroendocrine disorders (breast, ovarian dysfunction and cystic changes, uterine fibroids, endometriosis, infertility);the various manifestations of the climacteric syndrome;

individuals engaged in physical culture and sports (any age category, from juniors to veterans age) in training and competition cycle, as a means of increasing the efficiency and increasing the threshold of fatigue;

rehabilitation of athletes after injuries and leaving the “big” sports.

Contraindications

individual intolerance to the components of the drug;

liver and kidney diseases (end-stage cirrhosis of the liver and chronic renal failure.

Side effects

Milife® in any dosage has no carcinogenic, mutagenic, teratogenic, or embryotoxic properties. Milife® does not contain any xenobiotics, preservatives or any substances that lead to the development of allergic reactions.

In the course of detailed experimental studies of the drug, no side effects from its use were detected.

Interaction

Milife® can be combined with tetracycline, penicillin-type antibiotics, cephalosporins, macrolides, nitrofuran derivatives, naphthyridine, ursodeoxycholic and henodeoxycholic acids, fluoroquinolone-type drugs, while reducing the dose of antibiotics by 2/3 while taking Milife® at a dose of 1.0 g 6 times a day for 2-3 days.

A synergistic interaction of Milife® with gamma-amino-beta-phenylbutyric acid was revealed.

Milife ® enhances the action of peripheral vasodilators, antiarrhythmics, membrane stabilizers, anticonvulsants, antiparkinsonian agents, NSAIDs, but is not combined with aryl carboxylic acid derivatives and oxycams.

How to take, course of use and dosage

Substance: to prepare a solution for the treatment of wound surfaces and trophic ulcers,1 g of the drug is diluted in 50 ml of distilled water.

Tablets: sublingually (dissolve), after meals.

Capsules: inside, after meals.

In the course of studying the effect of the drug, two dosages were worked out that affect the body’s systems and the body as a whole-50 mg and 1 g.

The use of different dosages and their alternation is determined by specific preventive and therapeutic tasks. At a dose of 100 mg 3 times a day, broken connections are detected and restored in the body at the molecular and submolecular levels, subjectively this is manifested by various clinical symptoms of chronic pathology present in humans. At a dose of 1 g from 6 to 12 times a day, a positive effect on the pathological focus is directly carried out and defective cells are replaced, subjectively-relief of clinical manifestations.

The selection of the Milife® regimen is individual and depends on the initial status (immunological, neurohumoral, etc. ). :1. From day 1 to day 5: 100 mg 3 times a day. 2. From the 6th day for 12 weeks: Monday, Tuesday, Wednesday-100 mg 3 times a day; Thursday, Friday, Saturday, Sunday-1 g 3 times a day. 3. For women: intravaginally 200 mg, for 30 days (excluding menstrual days) from the 6th day of taking Milife®.4. Cedar oil for 1 dec. spoon 1 time on the days of taking Milife® for 1 g (Thursday, Friday, Saturday, Sunday).5. Physical exercises (classes).

After taking the initial scheme, the doctor decides whether it is necessary to continue taking Milife® according to an individual scheme.

For athletes and people who are intensively engaged in physical culture, the starting scheme is the same, but in the pre-start and start periods, the dose increases to 12 g/day (2 g 6 times). This scheme is approved by the Laboratory of Clinical Pharmacology and Anti-doping Control of the Moscow Scientific and Practical Center for Sports Medicine.

Special instructions

Based on a 15-year observation experience of people of different genders and ages taking Milife®, the following results were obtained.

Normalization of the level of all indicators (clinical and biochemical) of blood was noted.

Normalization of indicators of the T-and B-cell links of the immune system was noted.

The study of the hormonal profile showed a correlating effect of Milife® on the level of pituitary and ovarian hormones in the first and second phases of the menstrual cycle, a significant increase in progesterone in the ovulatory phase of the menstrual cycle. The anovulatory cycle was not observed in any of the women of reproductive age.

The data obtained indicate a significant stabilization and normalization of the neurohormonal profile in the reproductive ring of the hypothalamus-pituitary-adrenal-ovary, which allows us to recommend the drug Milife® to girls of the pre-and pubertal period in order to relieve the syndrome of psychoemotional lability, the formation and normalization of the menstrual cycle. Ultrasound revealed a decrease in the size of subserosal-interstitially located fibromatous nodes up to their complete lysis, a small percentage of women had “birth” of submucosal fibromatous nodes, the cellular structure of the myometrium and cystic degeneration of the ovaries disappeared.

After taking the drug, positive EEG dynamics were revealed in the form of normalization of the alpha rhythm, the appearance of zonal differences, and the disappearance of paroxysmal changes during functional loads. The revealed positive dynamics of the EEG indicates the normalization of the functional state of mesodiencephalic brain formations against the background of taking Milife® in more than 90% of those taking the drug.

Functional studies of brain vessels revealed no signs of venous stasis, blood filling in the carotid artery zones improved, and vascular tone in the vertebrobasilar basin normalized. Milife ® improves microcirculation not only by restoring the rheological properties of blood, but also by improving blood supply directly to the vessel wall itself (in particular, the epithelium).

Milife ® restores previously disturbed processes of neurohumoral regulation and energy resources of the myocardium, which is reflected in the improvement of contractile ability, relaxation function and positive inotropic stimulation of the heart. Restoration of bioenergetic processes improves the compensatory capabilities of the body, contributing to the work of the heart in a more economical mode.

In chronic latent forms of genital herpes and chlamydia, a massive release of infectious agents from cells and their subsequent elimination was detected, which is associated with the development of “short” immunity by the body. This contributed to the restoration of the microscopic structure of the mucous and muscle fibers of smooth muscles.

Milife ® increases the overall athletic performance of athletes by at least 30%, which is expressed in an increase in the time of running to failure on a treadmill with a stepwise increase in physical activity. A powerful antioxidant effect of the drug was revealed at the same time.

Morphologically, this effect was expressed in the stabilization of muscle mass against the background of fat mobilization, while in the control group there were signs of maladaptation to similar loads in the form of a total decrease in three morphological indicators (body weight, muscle mass, fat mass). Milife ® prevents an increase in the urea concentration in the blood of athletes (statistically significant by 17.8%), as well as a decrease in the level of hematocrit and lactate. There was an increase in the contractile capacity of the myocardium and an improvement in the propulsive work of the heart.

The function of the circulatory system was economized by increasing the ability of the muscles to use oxygen and improving the ability to isotonic contraction of the heart muscle.

Positive dynamics were observed in terms of myocardial contractility and systolic phase structure. Prolongation of the preexisting period indicated an improvement in the ability of the myocardium to create the necessary tension for a powerful contraction. The reduced value of intraventricular pressure created conditions for reducing tension in the left ventricular wall, which, together with reduced systolic indicators of the thickness of the posterior wall of the left ventricle and its size, contributed to a certain decrease in systolic meridional and circulatory stresses and an increase in the values of the index of functioning of structures. Assessment of diastolic function showed an improvement in the ability of myocardiocytes to accumulate the necessary energy reserve.

Restores immunological reactivity in high-class athletes, which is expressed in the normalization of the reduced concentration of immunoglobulins A, M and G; normalizes the level of complement components SZ and C%^%4 reduced due to debilitating physical exertion in athletes training for endurance development.

It has a favorable effect on the links of cellular immunity (phagocyte activity, phagocytosis intensity, lysosome activity, monocyte activity, increases the number of T-and B-lymphocytes). Normalizes factors of non-specific protection, such as the level of alpha-1-glycoprotein and alpha-2-glycoprotein, while the concentration of seromucoid and haptoglobin practically does not change.

Active ingredient

Fungi Fusarium Biomass

Conditions of release from pharmacies

Without a prescription

Dosage form

Tablets